Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 131Lymphoma 117Lymphoma, Large B-Cell, Diffuse 80Precursor Cell Lymphoblastic Leukemia-Lymphoma 55Multiple Myeloma 50Lymphoma, Non-Hodgkin 46Lymphoma, Follicular 45Leukemia 39Hodgkin Disease 33Lymphoma, Mantle-Cell 32Burkitt Lymphoma 31Lymphoma, Large-Cell, Immunoblastic 21Lymphoma, Large-Cell, Anaplastic 20Lymphoma, B-Cell, Marginal Zone 19Neoplasm Metastasis 16Leukemia, Lymphocytic, Chronic, B-Cell 16Neoplasms, Plasma Cell 15Neoplasms 13Lymphoma, T-Cell, Peripheral 10Dendritic Cell Sarcoma, Interdigitating 10Recurrence 9Lymphoma, B-Cell 9Primary Myelofibrosis 8Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Immunoblastic Lymphadenopathy 8Blast Crisis 7Lymphoma, T-Cell 6Graft vs Host Disease 6Waldenstrom Macroglobulinemia 5Prostate Cancer Metastatic 5

Interventions

Abiraterone Acetate 3enzalutamide 2abiraterone 2Prednisone 2sapanisertib 1relugolix 1onvansertib 1apalutamide 1abemaciclib 1Prednisolone 1Methylprednisolone 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Metastatic Castration-Resistant Prostate Cancer × Prednisone × Clear all
NCT04666129 2025-08-17

Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

Sumitomo Pharma America, Inc.

Phase 1 Completed
48 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT03414034 2024-11-07

Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer

Cardiff Oncology

Phase 2 Completed
72 enrolled 21 charts
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡